Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19026296 | MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18408259 | CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASES | January 2024 | July 2024 | Abandon | 6 | 1 | 1 | No | No |
| 18372623 | FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229E | September 2023 | February 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18372634 | FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229E | September 2023 | July 2024 | Allow | 9 | 2 | 1 | No | No |
| 18198100 | FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229E | May 2023 | November 2023 | Allow | 6 | 1 | 1 | Yes | No |
| 18089067 | NEUTROPHIL-BINDING PEPTIDES | December 2022 | January 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18053941 | Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use Thereof | November 2022 | August 2024 | Allow | 21 | 3 | 1 | No | No |
| 17937306 | ASSESSING AND TREATING AUTOIMMUNE ATAXIA | September 2022 | October 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17932600 | METHODS OF DETECTING ALLOANTIBODIES TO HLA CLASS II ANTIGENS | September 2022 | April 2025 | Allow | 31 | 0 | 1 | Yes | No |
| 17861954 | Engineered HLA Alleles for Treating Autoimmunity | July 2022 | December 2023 | Abandon | 18 | 0 | 1 | Yes | No |
| 17861943 | Methods of Treating Autoimmunity With Engineered HLA Proteins | July 2022 | April 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17843243 | NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF | June 2022 | February 2025 | Allow | 32 | 5 | 1 | Yes | No |
| 17746835 | COMPOSITION FOR CULTURING NATURAL KILLER CELLS AND METHOD FOR PREPARING NATURAL KILLER CELLS BY USING SAME | May 2022 | May 2025 | Allow | 36 | 4 | 1 | Yes | No |
| 17454225 | POPULATION-BASED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORM | November 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17517805 | IMMUNOGENIC PEPTIDES FOR USE IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, IMMUNE RESPONSES TO ALLOFACTORS, ALLERGIC DISEASES, TUMORS, GRAFT REJECTION AND IMMUNE RESPONSES AGAINST VIRAL VECTORS USED FOR GENE THERAPY OR GENE VACCINATION | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17448020 | PERSONALISED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORM | September 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17468095 | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17460104 | METHODS OF MAKING AND USING SOLUBLE MHC MOLECULES | August 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17390702 | MODULATION OF ANTIGEN IMMUNOGENICITY BY DELETING EPITOPES RECOGNIZED BY NKT CELLS | July 2021 | June 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17383265 | METHODS AND COMPOSITIONS FOR MODIFICATION OF HLA | July 2021 | June 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17375985 | CIML NK cells and Methods Therefor | July 2021 | August 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17191830 | Soluble Antibody Complexes for T Cell or NK Cell Activation and Expansion | March 2021 | March 2025 | Allow | 48 | 2 | 1 | No | No |
| 17178525 | CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS | February 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17130192 | MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSES | December 2020 | March 2025 | Abandon | 51 | 0 | 1 | No | No |
| 17247767 | ANTIBODIES AND METHODS OF USE THEREOF | December 2020 | November 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17127627 | POLYCLONAL GAMMA DELTA T CELLS FOR IMMUNOTHERAPY | December 2020 | January 2025 | Abandon | 49 | 0 | 1 | No | No |
| 16973877 | ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USE | December 2020 | November 2024 | Allow | 47 | 1 | 2 | No | No |
| 16953879 | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment | November 2020 | January 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17099286 | PEPTIDES | November 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17099267 | PEPTIDES DERIVED FROM PRORELAXIN H1 (RLN1) | November 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17099242 | PEPTIDES DERIVED FROM ACHAETE-SCUTE HOMOLOG 2 (ASCL2), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES | November 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17087363 | PEPTIDES | November 2020 | September 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17051410 | IMPROVED T-CELL THERAPY METHOD | October 2020 | April 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17081821 | DRY POWDER FORMULATIONS OF THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USE THEREOF | October 2020 | October 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 15733755 | BLOOD BIOMARKER FOR EOSINOPHILIC GASTROINTESTINAL DISORDERS | October 2020 | March 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17069136 | ANTI-WT1/HLA-SPECIFIC ANTIBODIES | October 2020 | September 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17017457 | PEPTIDES OF PAGE5 | September 2020 | April 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17017444 | CLAUDIN-6 PEPTIDES | September 2020 | March 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17013228 | PEPTIDES | September 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17010653 | PEPTIDES | September 2020 | March 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17009613 | ENHANCING T CELL ACTIVATION USING ALTERED MHC-PEPTIDE LIGANDS | September 2020 | October 2024 | Allow | 49 | 1 | 0 | No | No |
| 17001847 | SYNTAC POLYPEPTIDES AND USES THEREOF | August 2020 | December 2024 | Abandon | 51 | 1 | 1 | No | No |
| 16998945 | PEPTIDES DERIVED FROM KALLIKREIN 4 | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16994399 | PEPTIDES FROM PIWIL1 | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16992821 | FRAGMENTS OF P97 AND USES THEREOF | August 2020 | July 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16988431 | PEPTIDES | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16988425 | PEPTIDES | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16985797 | NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORS | August 2020 | August 2024 | Allow | 49 | 1 | 1 | No | No |
| 16985061 | PEPTIDES | August 2020 | February 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16985058 | PEPTIDES DERIVED FROM P ANTIGEN FAMILY MEMBER 2 (PAGE2) | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16945701 | Lyme Disease-Associated T Cell Receptor-Related Methods | July 2020 | May 2024 | Allow | 46 | 4 | 2 | Yes | No |
| 16938263 | PEPTIDES | July 2020 | January 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16931304 | Soluble HLA class II complexes and methods of production and uses thereof | July 2020 | April 2025 | Abandon | 57 | 1 | 1 | No | No |
| 16928977 | ANTIBODIES TO MICA AND MICB PROTEINS | July 2020 | January 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16959505 | MODIFIED MACROPHAGES AND MACROPHAGE PRECURSORS AND ASSOCIATED METHODS | July 2020 | November 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16767392 | UBIQUITOUS ANTIGENS FOR TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES | May 2020 | July 2024 | Allow | 49 | 2 | 2 | Yes | No |
| 16847808 | EXPANDED NK CELLS | April 2020 | February 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16835761 | METHOD FOR ACTIVATING HELPER T CELL | March 2020 | May 2025 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16811063 | METHOD FOR MASS PRODUCING NATURAL KILLER CELL AND USE OF NATURAL KILLER CELL OBTAINED BY THE METHOD AS ANTI-CANCER AGENT | March 2020 | June 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16796226 | Mononuclear Cell Derived NK Cells | February 2020 | October 2024 | Allow | 55 | 2 | 1 | Yes | No |
| 16751638 | ACTIVATION OF iNKT CELLS | January 2020 | November 2023 | Abandon | 46 | 1 | 0 | No | No |
| 16743849 | Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses Thereof | January 2020 | August 2024 | Abandon | 55 | 1 | 1 | No | No |
| 16743940 | COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR TREATMENT OF GRAFT VERSUS HOST DISEASE | January 2020 | May 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16617622 | MMP-8 AS A MARKER FOR IDENTIFYING INFECTIOUS DISEASE | November 2019 | June 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16685424 | COMPOUND COMPRISING AN AUTOANTIGENIC PEPTIDE AND A CARRIER WITH A MHC BINDING MOTIF | November 2019 | October 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16685765 | METHOD FOR THE ABSOLUTE QUANTIFICATION OF NATURALLY PROCESSED HLA-RESTRICTED CANCER PEPTIDES | November 2019 | January 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16610133 | IMPROVED LAMP CONSTRUCTS COMPRISING CANCER ANTIGENS | November 2019 | March 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16662808 | HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS | October 2019 | January 2025 | Abandon | 60 | 4 | 2 | No | No |
| 16569691 | METHOD FOR HIGH THROUGHPUT PEPTIDE-MHC AFFINITY SCREENING FOR TCR LIGANDS | September 2019 | September 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16492898 | Antigen Discovery for T Cell Receptors Isolated from Patient Tumors Recognizing Wild-Type Antigens and Potent Peptide Mimotopes | September 2019 | December 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16548953 | NANOSCALE ARTIFICIAL ANTIGEN PRESENTING CELLS | August 2019 | October 2023 | Allow | 50 | 2 | 2 | No | No |
| 16510442 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | July 2019 | December 2023 | Allow | 53 | 2 | 1 | No | No |
| 16507589 | BETA-2 MICROGLOBULIN-DEFICIENT CELLS | July 2019 | August 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16465675 | METHOD OF VALIDATING THE TRIGGERING OF AN IMMUNE RESPONSE TO A NEOEPITOPE OF A TUMOR WITH T-CELLS | May 2019 | April 2024 | Allow | 59 | 4 | 1 | Yes | No |
| 16366320 | MODIFIED A1-A2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND NON-NATURAL NKG2D RECEPTORS | March 2019 | July 2024 | Allow | 60 | 3 | 1 | No | No |
| 16354605 | METHOD FOR PRODUCING NK CELL-ENRICHED BLOOD PREPARATION | March 2019 | November 2023 | Abandon | 57 | 5 | 0 | Yes | No |
| 16228763 | METHOD FOR IN VITRO ACTIVATION AND/OR EXPANSION OF IMMUNE CELLS | December 2018 | October 2023 | Allow | 57 | 2 | 1 | Yes | No |
| 16312956 | MHC-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES | December 2018 | November 2023 | Abandon | 59 | 2 | 1 | No | No |
| 16301381 | PEPTIDE EXCHANGE SYSTEM AND METHOD | November 2018 | March 2024 | Allow | 60 | 2 | 2 | No | No |
| 16173150 | MULTISPECIFIC NK ENGAGER PROTEIN | October 2018 | November 2024 | Allow | 60 | 4 | 1 | No | No |
| 16122562 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | September 2018 | September 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16044866 | NATURAL KILLER CELLS WITH ENHANCED IMMUNE RESPONSE | July 2018 | August 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16015955 | MHC Multimers, Methods for Their Generation, Labeling and Use | June 2018 | May 2024 | Abandon | 60 | 3 | 1 | No | Yes |
| 16008430 | REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE | June 2018 | August 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
| 15780623 | MODIFIED CHIMERIC RECEPTORS AND RELATED COMPOSITIONS AND METHODS | May 2018 | July 2024 | Allow | 60 | 5 | 2 | Yes | No |
| 15780624 | COMPOSITIONS AND METHODS FOR REDUCING IMMUNE RESPONSES AGAINST CHIMERIC ANTIGEN RECEPTORS | May 2018 | October 2023 | Allow | 60 | 3 | 2 | No | No |
| 15773952 | IMMUNOTHERAPY | May 2018 | July 2023 | Allow | 60 | 3 | 1 | Yes | No |
| 15750607 | IDENTIFICATION OF CLASS I MHC ASSOCIATED GLYCOPEPTIDES AS TARGETS FOR CANCER IMMUNOTHERAPY | February 2018 | October 2022 | Abandon | 56 | 4 | 1 | No | No |
| 15807415 | RECOMBINANT pMHC CLASS II MOLECULES | November 2017 | March 2022 | Abandon | 52 | 6 | 1 | Yes | No |
| 15572137 | NANOPARTICLE COMPOSITIONS FOR SUSTAINED THERAPY | November 2017 | November 2023 | Allow | 60 | 6 | 1 | Yes | No |
| 15555613 | COMPOSITIONS AND METHODS FOR ENHANCING AN IMMUNE RESPONSE | September 2017 | February 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 15536428 | ARTIFICIAL MULTI-ANTIGEN FUSION PROTEIN AND PREPARATION AND USE THEREOF | June 2017 | September 2023 | Allow | 60 | 5 | 1 | Yes | No |
| 15436400 | STIMULATION OF THERAPEUTIC ANGIOGENESIS BY T REGULATORY CELLS | February 2017 | May 2019 | Allow | 27 | 4 | 1 | Yes | No |
| 15027148 | Nanoparticle Based Artificial Antigen Presenting Cell Mediated Activation of NKT Cells | April 2016 | June 2023 | Allow | 60 | 6 | 1 | Yes | No |
| 14973033 | MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS | December 2015 | November 2017 | Allow | 23 | 2 | 1 | Yes | No |
| 14732145 | COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE | June 2015 | June 2016 | Allow | 13 | 2 | 0 | No | No |
| 14695841 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | April 2015 | June 2016 | Allow | 14 | 1 | 0 | No | No |
| 14122937 | NOVEL ANTIGEN PEPTIDE AND USES THEREOF | February 2014 | December 2015 | Allow | 24 | 4 | 1 | Yes | No |
| 13924275 | COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE | June 2013 | January 2015 | Allow | 19 | 1 | 0 | No | No |
| 13731711 | MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS | December 2012 | September 2015 | Allow | 32 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DIBRINO, MARIANNE.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DIBRINO, MARIANNE works in Art Unit 1641 and has examined 168 patent applications in our dataset. With an allowance rate of 72.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 48 months.
Examiner DIBRINO, MARIANNE's allowance rate of 72.0% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DIBRINO, MARIANNE receive 2.65 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DIBRINO, MARIANNE is 48 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +53.9% benefit to allowance rate for applications examined by DIBRINO, MARIANNE. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.0% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 45.8% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 92.3% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.2% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.3% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 18.2% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.